Related Experiment Video
Updated: Aug 11, 2026

Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
Published on: November 8, 2017
Serum S-100beta as a possible marker of blood-brain barrier disruption
M Kapural1, Lj Krizanac-Bengez, G Barnett
1Department of Neurological Surgery, Cleveland Clinic Foundation NB-20, 9500 Euclid Avenue, NB2-137, Cleveland, OH 44195, USA.
Abstract:
Two brain-specific proteins, S-100beta and neuron-specific enolase (NSE), are released systemically after cerebral lesions, but S-100beta levels sometimes rise in the absence of neuronal damage. We hypothesized that S-100beta is a marker of blood-brain barrier (BBB) leakage rather than of neuronal damage. We measured both proteins in the plasma of patients undergoing iatrogenic BBB disruption with mannitol, followed by chemotherapy. Serum S-100beta increased significantly after mannitol infusion (P<0.05) while NSE did not. This suggests that S-100beta is an early marker of BBB opening that is not necessarily related to neuronal damage.

